Earnings Summary

Abrdn Life Sciences Investors’s revenue jumped 584.24% since last year same period to $9.82Mn in the Q1 2023. On a quarterly growth basis, Abrdn Life Sciences Investors has generated 918.1% jump in its revenue since last 3-months.

Abrdn Life Sciences Investors’s net profit jumped 144.3% since last year same period to $33.8Mn in the Q1 2023. On a quarterly growth basis, Abrdn Life Sciences Investors has generated 100% jump in its net profits since last 3-months.

Abrdn Life Sciences Investors’s net profit margin jumped 106.48% since last year same period to 344.19% in the Q1 2023. On a quarterly growth basis, Abrdn Life Sciences Investors has generated -80.36% fall in its net profit margins since last 3-months.

Abrdn Life Sciences Investors’s price-to-earnings ratio after this Q1 2023 earnings stands at 16.2.

Abrdn Life Sciences Investors’s earning per share (EPS) estimates for the current year stand at 0.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Abrdn Life Sciences Investors’s return on assets (ROA) stands at -0.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Abrdn Life Sciences Investors’s return on equity (ROE) stands at 0.01.

Abrdn Life Sciences Investors declared 0.33 dividend per share during the earnings announcement for Q1 2023.